Aristeia Capital L.L.C. Purchases Shares of 1,896 DaVita Inc. $DVA

Key Points

• Aristeia Capital L.L.C. has purchased 1,896 shares of DaVita Inc., valued at approximately $290,000, as reported in their recent SEC filing.
• The stock has seen recent activity from institutional investors, with a total of 90.12% of DaVita's stock owned by institutions and hedge funds.
• Despite a strong quarterly earnings report, DaVita's stock has seen a 2.5% decrease in trading, with an average price target from analysts of $164.00.

Aristeia Capital L.L.C. purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,896 shares of the company's stock, valued at approximately $290,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. UMB Bank n.a. lifted its holdings in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares during the last quarter. Copia Wealth Management acquired a new stake in DaVita in the 4th quarter valued at about $30,000. National Pension Service lifted its holdings in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after acquiring an additional 84 shares during the last quarter. Y.D. More Investments Ltd acquired a new stake in DaVita in the 1st quarter valued at about $35,000. Finally, NewEdge Advisors LLC lifted its holdings in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock valued at $78,000 after acquiring an additional 88 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider owned 26,038 shares in the company, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.50% of the stock is currently owned by company insiders.

DaVita Trading Down 2.5%

NYSE:DVA opened at $134.44 on Tuesday. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The stock's 50 day moving average price is $139.24 and its 200 day moving average price is $141.76. The company has a market capitalization of $9.61 billion, a P/E ratio of 13.22, a P/E/G ratio of 0.99 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter last year, the company posted $2.00 earnings per share. The company's revenue for the quarter was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on DVA shares. Barclays reduced their price objective on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Truist Financial set a $148.00 price objective on shares of DaVita in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, August 22nd. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $164.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.